½ðºÌÓéÀÖ³Ç

- Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant¡¯s ability to participate in this study. - Female participants who are breastfeeding, pregnant, or plan to become pregnant during the study. - Participant has an active infection or a history of recent serious infections. - Participant has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection. - Study participant has a diagnosis of inflammatory conditions other than PSO or PsA including, but not limited to, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, reactive arthritis, and axial spondyloarthritis. - Study participants with a history of anterior uveitis are allowed if they have no active symptoms at Screening or Baseline. Study participants with a diagnosis of Crohn¡¯s disease or ulcerative colitis are allowed if they have no active symptomatic disease at Screening or Baseline. - Study participants with fibromyalgia or osteoarthritis symptoms that in the Investigator¡¯s opinion would have potential to interfere with efficacy assessments. - Participant has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer. - Participant has a history of chronic alcohol or drug abuse within 6 months prior to Screening. - Study participants taking psoriatic arthritis (PsA) medications other than MTX, SSZ, apremilast, hydroxychloroquine (HCQ), LEF, nonsteroidal anti-inflammatory drug (NSAIDs)/ cyclooxygenase-2 (COX-2) inhibitors, oral corticosteroids, and analgesics as outlined in the Inclusion criteria. - Study participant is taking or has taken prohibited PsA or PSO medications without meeting the mandatory wash-out period relative to the Baseline Visit. - Study participant is taking or has taken janus kinase (JAK) inhibitor. - Study participant is taking or has taken bDMARDs, including bimekizumab or risankizumab, with the exception of having received 1 prior TNF¦Á inhibitor. - Study participant previously participated in another study of a medical device under investigation within the 4 weeks prior to the Screening Visit or is currently participating in another study of a medical device under investigation.